Month: January 2023
MALVERN, Pa., Jan. 19, 2023 (GLOBE NEWSWIRE) — Vishay Precision Group, Inc. (NYSE: VPG), a leader in precision measurement and sensing technologies, will release its financial results for the fourth quarter and full year of fiscal 2022 after the close of the market on Tuesday, February 14, 2023.
Ziv Shoshani, chief executive officer, and Bill Clancy, chief financial officer, will host a conference call the following day on Wednesday, February 15, 2023 at 9:00 a.m. ET (8:00 a.m. CT). To access the conference call, interested parties should call 1-844-200-6205 or internationally +1-929-526-1599 and use passcode 467007, or may access the live webcast by visiting the “Events” page of investor relations section of the VPG website at http://ir.vpgsensors.com.
A webcast replay will be available for a limited time approximately one hour...
Midland Provides an Overview of Its 2023 Exploration Activities With Its Partners and to Follow-Up on Its New Discoveries
Written by Customer Service on . Posted in Public Companies.
Figure 1
Abitibi-Midland Projects & JV’sFigure 2
James Bay Geology-Midland ProjectsFigure 3
Nunavik-Midland Projects&AlliancesFigure 4
Rio Tinto Tete Nord – 2023 Drilling AreasMONTREAL, Jan. 19, 2023 (GLOBE NEWSWIRE) — Midland Exploration Inc. (“Midland”) (TSX-V: MD) is pleased to provide an overview of its plans for 2023 in Quebec with exploration activities aimed at following up on its new discoveries made throughout 2022.
In 2023, Midland will continue to apply its business model as a “Project Generator” with the recent acquisition of several new high-quality properties and the formation of several new partnerships across Quebec, including new partnerships for lithium exploration in the James Bay region. With an exploration budget for 2023 estimated at more than $11 million and 20,000 metres...
Sunshine Biopharma Announces Share Repurchase Program
Written by Customer Service on . Posted in Public Companies.
MONTREAL, Jan. 19, 2023 (GLOBE NEWSWIRE) — Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced its board of directors has authorized a share repurchase program to acquire up to $2 million of the Company’s common stock.
The Company may purchase common stock on the open market, through privately negotiated transactions, or otherwise, in compliance with the rules of the United States Securities and Exchange Commission and other applicable legal requirements. As of September 30, 2022, the Company had approximately $40.5 million of cash and cash equivalents. The Company had approximately 22.6 million shares of common stock issued and outstanding as of November 7, 2022.
Dr. Steve Slilaty, CEO...
Bellicum Pharmaceuticals to Present Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO 2023 Genitourinary Cancers Symposium
Written by Customer Service on . Posted in Public Companies.
HOUSTON, Jan. 19, 2023 (GLOBE NEWSWIRE) — Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that an abstract on early results from a Phase 1 clinical trial for BPX-601, its lead GoCAR-T® product candidate, has been accepted for poster presentation at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU). The meeting is being held February 16-18, 2023 in San Francisco and virtually. The ongoing trial is being conducted in patients with metastatic castration-resistant prostate cancer.
Details of the poster presentation are as follows:
Title: Early Results from a Phase 1, Multicenter Trial of PSCA-Specific GoCAR-T Cells (BPX-601) in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)Poster...
HydroGraph to Begin Trading on the OTCQB Exchange Under the Ticker Symbol HGCPF
Written by Customer Service on . Posted in Public Companies.
VANCOUVER, British Columbia, Jan. 19, 2023 (GLOBE NEWSWIRE) — HydroGraph Clean Power Inc. (HG.CN) (the “Company” or “HydroGraph”), a commercial manufacturer of high-quality graphene and other nanomaterials is pleased to announce that the Company’s common shares were approved for trading on the OTCQB Venture Market (the “OTCQB”) with DTC certification, under the symbol “HGCPF”. The Company’s common shares will continue to trade on the Canadian Stock Exchange under the trading symbol “HG”.
“HydroGraph is scaling the commercialization of our high-quality graphene while continuing to revolutionize science and technology and grow operations across a variety of industries including resins, coatings, and lubricants,” said Stuart Jara, a director and Chief Executive Officer of HydroGraph. “Getting the U.S. OTCQB...
iSpecimen to Participate in Maxim’s Healthcare IT Virtual Conference on January 25, 2023
Written by Customer Service on . Posted in Public Companies.
LEXINGTON, Mass., Jan. 19, 2023 (GLOBE NEWSWIRE) — iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists in need of biospecimens for medical research with a network of healthcare specimen providers, today announced that Tracy Curley, CEO of iSpecimen, will participate in the Healthcare IT Virtual Conference hosted by Maxim Group and M-Vest on Wednesday, January 25, 2023.
Ms. Curley will present at 8:30 a.m. ET. To attend, please register here.
For more information about the conference, or to schedule a one-on-one meeting with iSpecimen’s management team, please contact your appropriate Maxim representative, or send an email to KCSA Strategic Communications at iSpecimen@kcsa.com.
About iSpecimeniSpecimen (Nasdaq: ISPC) offers an online marketplace for human biospecimens,...
GEN3 PUREVAP™ QRR Pilot Plant: Process Testing Moving Forward on Schedule
Written by Customer Service on . Posted in Public Companies.
MONTREAL, Jan. 19, 2023 (GLOBE NEWSWIRE) — HPQ Silicon Inc. (“HPQ” or the “Company”) (TSX-V: HPQ) (OTCQX: HPQFF) (FRA: O08), a technology company engaged in green engineering processes of producing silica and silicon material, would like to inform investors of the next milestones planned as its GEN3 PUREVAPTM Quartz Reduction Reactor (QRR) (“GEN3 QRR”) (“Pilot Plant”) testing program passes the halfway mark.
During the past six (6) months of the program technology provider PyroGenesis Canada Inc. (TSX: PYR) (NASDAQ: PYR) (FRA: 8PY), validated that the GEN3 QRR pilot plant operates as designed and produces Silicon (Si) Materials.
Having passed the halfway mark, the remaining months of the program will focus on achieving key milestones that will dictate the start and end of a series of process improvement tests. These three series...
American National Bankshares Reports Fourth Quarter and Full Year 2022 Earnings
Written by Customer Service on . Posted in Public Companies.
DANVILLE, Va., Jan. 19, 2023 (GLOBE NEWSWIRE) — American National Bankshares Inc. (NASDAQ: AMNB) (“American National” or the “Company”) today reported fourth quarter 2022 earnings of $8.0 million, or $0.76 per diluted common share. Those results compare to earnings of $11.3 million, or $1.05 per diluted common share, during the same quarter in the prior year, and earnings of $9.3 million, or $0.87 per diluted common share, for the third quarter of 2022. Earnings for the twelve months ended December 31, 2022 were $34.4 million, or $3.23 per diluted common share, compared to $43.5 million, or $4.00 per diluted common share, for the same period of 2021.
President and Chief Executive Officer, Jeffrey V. Haley, commented, “American National finished 2022 on a positive note with strong earnings for the fourth quarter and the full year....
Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas’ iNK Cell Franchise and Related Gene Editing Technologies
Written by Customer Service on . Posted in Public Companies.
Shoreline to obtain an exclusive license to SLEEK knock-in technology for iPSC-derived NK cells, an exclusive license to SLEEK for iPSC-derived macrophages in oncology and a non-exclusive license for AsCas12a
Shoreline to acquire Editas Medicine’s iNK cell franchise, including EDIT-202 and certain related manufacturing technologies
Economics to Editas Medicine to include upfront payment, and development and commercial milestone and royalty payments
CAMBRIDGE, Mass. and SAN DIEGO, Jan. 19, 2023 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it has entered into a definitive agreement with Shoreline Biosciences (Shoreline) for Shoreline to license Editas Medicine’s proprietary SLEEK (SeLection by Essential-gene Exon Knock-in) and AsCas12a gene editing technologies...
OneWater Marine Inc. Announces Fiscal First Quarter 2023 Earnings Release Date and Conference Call Information
Written by Customer Service on . Posted in Public Companies.
BUFORD, Ga., Jan. 19, 2023 (GLOBE NEWSWIRE) — OneWater Marine Inc. (NASDAQ: ONEW) (the “Company” or “OneWater”) announced today that it will release its first quarter 2023 financial results on Thursday, February 2, 2023, before the market opens. Following the release, the Company’s management team will host a conference call to discuss the results at 8:30 a.m. Eastern Time that day.
To access via phone, participants will need to register using the following link where they will be provided a phone number and access code:
https://register.vevent.com/register/BI7ed348a781b44352aadaa744402ac065
Alternatively, a live webcast of the conference call can be accessed through the “Events” section of the Company’s website at https://investor.onewatermarine.com/ where it will be archived for one year.
About OneWater Marine Inc. OneWater Marine...